Navigation Links
Heptares Secures GBP21 Million in Series A Fund Raising to Accelerate Development of Pipeline of Small Molecules Against High-Value GPCR Drug Targets
Date:2/24/2009

o supporting the experienced management team in fulfilling the potential of Heptares' innovative approach."

Dr David Tapolczay, CEO of Medical Research Council Technology, said: "Heptares is a prime example of the importance of MRC's long-term support for basic biomedical research and the potential for discoveries to translate into a commercial enterprise that is dedicated to producing better medicines. The fact that Heptares has attracted such a strong investor syndicate and funding round so early in its development also shows how quickly this translation of basic research into significant health benefits can be made to occur."

Notes to Editors

About Heptares Therapeutics Ltd

Heptares is a drug discovery company focused on the discovery of novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs). The Company is deploying its proprietary StaR(TM) technology principally against highly validated but currently difficult or intractable GPCR targets in several disease areas.

GPCRs are the single most important family of drug targets in the human body, but because of their inherent instability they are refractory to structural studies and in vitro screening. StaR technology enables the engineering of stabilised GPCRs, making them amenable to these vital drug discovery approaches. There are many clinically relevant GPCR targets across a wide range of therapeutic areas where discovery is advancing slowly and for which structural information, novel screening approaches and potential antibody therapeutics would greatly enhance progress.

Heptares was founded in 2007 and its StaR technology arose out of the pioneering work of Heptares' founding scientists, Richard Henderson and Chris Tate at the MRC Laboratory of Molecular Biology (Cambridge, UK) and of a wider group of MRC scientists, including Gebhard Schertler, and Ed Hulme of the National Institute for M
'/>"/>

SOURCE Heptares Therapeutics Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Northwest Biotherapeutics Secures $700,000 Equity Financing
3. Intelligroup Secures Multi-Million Dollar COSMOS Implementation with Almac Clinical Services
4. TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
5. Pharmacyclics Secures $5.0 Million in Debt Financing
6. EcoSphere(R) Biolatex(TM) Secures Funding from Granholm and Invest Michigan!
7. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
8. Queens secures £25M for UKs cyber safety
9. Queens secures £25m for UKs cyber-safety
10. Northwest Secures US$1.65 Million Debt Financing
11. NeoStem Secures $250,000 in an Above Market Financing and Expands Its Relationship With New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... the Company,s Chief Financial Officer has resigned.  The Company ... Financial Officer who retired in December 2014, as full ... a permanent successor.     Andy Ashworth ... and ensure a smooth transition.  Andy was the Company,s ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... supplier, announces the launch of their 2nd generation cell therapy POD® design. The ... CT, but it also represents a new POD® design. , “G-CON first ...
(Date:7/29/2015)... CHICAGO , July 29, 2015  AmnioChor Inc., ... cell technology, is very pleased to announce that the ... has agreed to invest in their seed round ... OmniBank placental tissue storage capabilities. AmnioChor,s ... placenta, and the human stem cells living within those ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... RainDance Technologies, Inc., a,provider of innovative microdroplet-based ... the relocation of the company from,Guilford, Connecticut, to ... facility and start up commercial and manufacturing operations,effective ... our first life sciences application scheduled for,the fourth ...
... Epeius Biotechnologies,announced today the results of an on-going ... et al., ASCO meeting, 2008).,Continuing on with the planned ... of Rexin-G in a Phase I safety study (Molecular,Therapy, ... Rexin-G given i.v. two to three times a week ...
... Replikins Ltd. has found that very high,concentrations ... the,trypanosomes that are the infectious agents in malaria. ... the highest replikin concentrations observed to,date in any ... that these,concentrations cycle over several years., Replikins ...
Cached Biology Technology:RainDance Announces Company Relocation and Manufacturing Startup 2ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer 2Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes 2
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. ... of human interface solutions, today announced a ... first fully hardware encapsulated fingerprint sensor and ... technology is literally off the grid, isolating ... matching within the fingerprint sensor to provide ...
(Date:7/7/2015)... -- Research and Markets ( ... "Capacitive Fingerprint Sensors Patent Landscape" report ... fingerprint sensing technology is the most reliable and ... developed. This patent landscape focuses on fingerprint sensors ... of capacitive fingerprint sensors is closely linked to ...
(Date:7/2/2015)... , July 2, 2015 Fingerprint Cards ... FPC1035, FPC1145 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of approximately 2,200 MSEK ...
Breaking Biology News(10 mins):Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2
... first time, large-scale information on the biochemical makeup ... publicly. These molecules are used in research to ... disease. Making these data accessible to researchers worldwide ... patients. NIH,s National Center for Advancing ...
... As coastal communities continue to rebuild in the ... meeting of the American Geophysical Union offer some encouraging ... barrier system that controls erosion on Long Island. Long-term ... sea-level rise, pollutants churned up by the storm within ...
... , Dec. 10, 2013  KaloBios Pharmaceuticals, Inc. ... results of an ongoing multi-center Phase 1 study ... company is developing as a treatment for hematologic ... were unfit for chemotherapy have been enrolled in ...
Cached Biology News:Gene-silencing data now publicly available to help scientists better understand disease 2Gene-silencing data now publicly available to help scientists better understand disease 3Post-Sandy, Long Island barrier systems appear surprisingly sound 2Post-Sandy, Long Island barrier systems appear surprisingly sound 3KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 2KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 3KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 4KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 5
... Acetate: CoA ligase (AMP forming), Acetate ... on protein content. Physical form: ... sucrose and reduced glutathione Preparation ... mol of S-acetyl coenzyme A from acetate, ...
...
... 15(S)-15-methyl PGF2α is a ... It is a potent uterine ... be administered intramuscularly to induce ... reduces serum progesterone concentrations when ...
... Biochem/physiol Actions: Glutathione-S-transferases (GSTs) are a group ... many xenobiotics in mammals. The enzymes ... thiol group of the glutathione to electrophilic ... mutagenic, carcinogenic, and toxic effects of the ...
Biology Products: